Print this page
-
Exploring Patient and Caregiver Perspectives and Experiences with Financial Toxicity.
Protocol: 132105Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Leukemia, not otherwise specified
Myeloid and Monocytic Leukemia
Hodgkin's Lymphoma
Leukemia, other -
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Protocol: 082304Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate -
A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Protocol: 082401Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Multicenter, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy.
Protocol: 082106Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE].
Protocol: 081910Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney -
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Kidney
- 1
- 2